Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma
Status:
Completed
Trial end date:
2004-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Denileukin diftitox may be able to deliver cancer-killing substances directly to
T-cell lymphoma cells. Dexamethasone may decrease the side effects of denileukin diftitox.
PURPOSE: Phase II trial to study the effectiveness of dexamethasone in preventing side
effects following treatment with denileukin diftitox in treating patients who have persistent
or recurrent T-cell lymphoma.